Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Assessment of Cytotoxic Properties of Tetrahydroisoquinoline Oximes in Breast, Prostate, and Glioblastoma Cancer Cells

April 15, 2025

[Drug and Chemical Toxicology] Recent studies have shown that some tetrahydroisoquinoline (THIQ) oximes induce cytotoxic effects and trigger apoptosis in various cell types. Since this pathway activation is desirable for anticancer drugs, scientists further explored the effects of three selected THIQ oximes on well-known cancer cell models: breast, prostate cancer, and malignant glioblastoma).

Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer

April 15, 2025

[Journal of Medicinal Chemistry] Investigators reported an effective and selective PRMT7 inhibitor which was obtained through structural optimization and exhibited potent anti-prostate cancer efficacy in vitro and in vivo.

Reprogramming of Androgen Receptor Activity in Castration-Resistant Prostate Cancer Is Shaped by Truncated Variants

April 15, 2025

[European Urology Focus] Scientists determined how truncated variants shape androgen receptor (AR) chromatin occupancy and responses to treatments in both the presence and absence of full-length AR.

Validation and Derivation of MicroRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer

April 11, 2025

[Clinical Cancer Research] Scientists validated a previously identified biomarker of late radiation therapy (RT)-induced genitourinary (GU)toxicity, PROSTOX, consisting primarily of microRNA-based germline biomarkers (mirSNPs), and investigated the possibility of temporally and genetically defining other forms of RT-associated GU toxicity.

TOR1 AIP1 Interacts with P53 to Enhance Cell Cycle Dysregulation in Prostate Cancer Progression

April 11, 2025

[Molecular and Cellular Biochemistry] Researchers analyzed the expression and survival data of TOR1 AIP1 in prostate adenocarcinoma (PRAD) patients in the TCGA database and verified the low expression of TOR1 AIP1 in prostate cancer by qPCR, western blot and immunohistology, which was correlated with the tumor stage and survival prognosis of PRAD.

Discovery of Novel Tetrahydroquinoline Derivatives As Potent, Selective, and Orally Available AR Antagonists

April 11, 2025

[European Journal of Medicinal Chemistry] Investigators discovered a novel tetrahydroquinoline derivative that demonstrated excellent oral bioavailability, indicating the potential to enhance in vivo efficacy and to serve as a promising therapeutic option for prostate cancer treatment.

Androgen Receptor-Regulated lncRNA PRCAT71 Promotes AR Signaling through the Interaction with KHSRP in Prostate Cancer

April 11, 2025

[Science Advances] Scientists found an lncRNA, prostate cancer (PCa) -associated transcript 71 (PRCAT71), highly expressed in metastatic and primary PCa compared to benign prostate tissues.

NUF2 Activated by YY1 Promotes Prostate Cancer Malignancy via P38/MAPK Signaling Axis and Serves As a Therapeutic Target

April 10, 2025

[Biochemical Pharmacology] Researchers demonstrated that NUF2 was significantly overexpressed in prostate cancer, with its elevated levels correlating with poor patient survival outcomes.

Dual-Targeted Alpha Therapy Mitigates Prostate Cancer and Boosts Immune Checkpoint Blockade Therapy

April 10, 2025

[Journal of Controlled Release] Investigators reported on Sigma-1 receptor and PSMA dual-specific peptide with efficient 225‑actinium labeling for targeted alpha therapy and alpha-immunotherapy of murine prostate tumors.

Reduced Store Operated Calcium Entry Contributes to Autophagy Mediated Escape of Prostate Cancer to Oxaliplatin Treatment

April 10, 2025

[Biochimica Et Biophysica Acta-Molecular Cell Research] Researchers demonstrated that oxaliplatin treatment enhanced autophagy in prostate cancer cells.

Targeting the Tumor Cell Surface in Advanced Prostate Cancer

April 1, 2025

[Nature Reviews Urology] Surface proteins such as PSMA, B7-H3, STEAP1, DLL3, TROP2, PSCA, HER3, and CD46 are a promising class of novel therapeutic targets in prostate cancer.

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

March 27, 2025

[Telix Pharmaceuticals Limited] Telix announce that the US FDA has approved its New Drug Application for Gozellix®, Telix’s next-generation PSMA-PET imaging agent for prostate cancer.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.